TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.

Details

Ressource 1Download: 29295985_BIB_EF655037E4F5.pdf (3893.12 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_EF655037E4F5
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.
Journal
Nature communications
Author(s)
Conrad C., Di Domizio J., Mylonas A., Belkhodja C., Demaria O., Navarini A.A., Lapointe A.K., French L.E., Vernez M., Gilliet M.
ISSN
2041-1723 (Electronic)
ISSN-L
2041-1723
Publication state
Published
Issued date
02/01/2018
Peer-reviewed
Oui
Volume
9
Number
1
Pages
25
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2-5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction from classical psoriasis remain unknown. Here we show that skin lesions from patients with paradoxical psoriasis are characterized by a selective overexpression of type I interferons, dermal accumulation of plasmacytoid dendritic cells (pDC), and reduced T-cell numbers, when compared to classical psoriasis. Anti-TNF treatment prolongs type I interferon production by pDCs through inhibition of their maturation. The resulting type I interferon overexpression is responsible for the skin phenotype of paradoxical psoriasis, which, unlike classical psoriasis, is independent of T cells. These findings indicate that paradoxical psoriasis represents an ongoing overactive innate inflammatory process, driven by pDC-derived type I interferon that does not lead to T-cell autoimmunity.
Keywords
Adalimumab/adverse effects, Adalimumab/immunology, Adalimumab/therapeutic use, Adolescent, Adult, Aged, Animals, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/immunology, Antibodies, Monoclonal/therapeutic use, Autoimmunity/drug effects, Autoimmunity/immunology, Cells, Cultured, Crohn Disease/drug therapy, Crohn Disease/immunology, Crohn Disease/metabolism, Cytokines/genetics, Cytokines/immunology, Cytokines/metabolism, Dendritic Cells/drug effects, Dendritic Cells/immunology, Dendritic Cells/metabolism, Female, Humans, Infliximab/adverse effects, Infliximab/immunology, Infliximab/therapeutic use, Interferon Type I/genetics, Interferon Type I/immunology, Interferon Type I/metabolism, Male, Mice, Inbred BALB C, Middle Aged, Psoriasis/chemically induced, Psoriasis/immunology, T-Lymphocytes/drug effects, T-Lymphocytes/immunology, T-Lymphocytes/metabolism, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha/immunology, Tumor Necrosis Factor-alpha/metabolism, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
16/01/2018 15:22
Last modification date
30/04/2021 6:16
Usage data